Novartis and Amgen announce FDA approval of Aimovig™ …
https://www.novartis.com/us-en/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-aooe-novel-treatment-developed-specifically-migraine-prevention
WEBMay 17, 2018 · Aimovig is the only FDA-approved treatment specifically developed to prevent migraine by blocking the CGRP-R, which is associated with migraine. Aimovig has been studied in several large global, randomized, double-blind, placebo-controlled studies to assess its safety and efficacy in migraine prevention.
DA: 97 PA: 78 MOZ Rank: 12